Advertisement

New Jersey medical device maker C.R. Bard closes a previously announced acquisition of Medafor, a deal worth up to $280 million in cash and milestone payments.

Bard puts a ribbon on $280M Medafor acquisition

C.R. Bard (NYSE:BCR) tied a bow on its previously announced acquisition of Minnesota-based Medafor in a deal worth up to $280 million.

Officially consummated on October 1, the deal provided $200 million up-front and another possible $80 million for Medafor and its line of anti-bleeding agents.

Advertisement
Advertisement